Pharmaceutical Research Institute , 8 Rydygiera, Warsaw 02-785 , Poland
Expert Opin Ther Pat. 2014 Jun;24(6):633-46. doi: 10.1517/13543776.2014.898061. Epub 2014 Mar 22.
The hypothesis that retiferols are a novel class of vitamin D analogs with therapeutic potential has been recently proved. The CD-ring of vitamin D, originated from a steroid precursor, is not necessary for biological activity. The retiferol, disubstituted at C-13, was bound to the ligand-binding domain (LBD) of vitamin D receptor (VDR) just like the vitamin D hormone [1,25-(OH)2D3]. This finding opens the way for retiferols as a novel class of vitamin D therapeutics.
This review presents the concept of retiferols and their structure evolution. Medicinal chemistry and therapeutic perspective of retiferols are reviewed showing how these vitamin D analogs became a source of potential therapeutics.
Docking experiments and molecular modeling have shown that positioning of vitamin D analog at the LBD of VDR is not disturbed by deletion of a large portion of the vitamin D, exactly as hypothesized. Twenty years of structural modifications have shown that removal of the CD-ring fragment and regioselective methylation results in an almost complete loss of the undesired calcemic activity of retiferol while gaining the agonistic activity comparable to that of 1,25-(OH)2D3.
最近已经证明,视黄醇是一类具有治疗潜力的新型维生素 D 类似物的假说。维生素 D 的 CD 环来源于甾体前体,对于生物活性不是必需的。视黄醇在 C-13 处被取代,与维生素 D 受体 (VDR) 的配体结合域 (LBD) 结合,就像维生素 D 激素 [1,25-(OH)2D3] 一样。这一发现为视黄醇作为一类新型维生素 D 治疗药物开辟了道路。
本文介绍了视黄醇的概念及其结构演变。综述了视黄醇的药物化学和治疗观点,展示了这些维生素 D 类似物如何成为潜在治疗药物的来源。
对接实验和分子建模表明,维生素 D 类似物在 VDR 的 LBD 中的定位不受维生素 D 大部分缺失的干扰,正如假设的那样。二十年来的结构修饰表明,去除 CD 环片段和区域选择性甲基化导致视黄醇失去了不必要的钙调活性,而获得了与 1,25-(OH)2D3 相当的激动活性。